Lycera Corp., a biopharmaceutical company creating innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that it has reached the first milestone under its research collaboration with Merck, triggering a milestone payment.
New research from the Grand Rapids-based Van Andel Research Institute demonstrates on the molecular level how the anti-malaria drug chloroquine represses inflammation, which may provide a blueprint for new strategies for treating auto-immune diseases from […]
Lycera, a biopharmaceutical company and University of Michigan spinoff, plans to partner and collaborate with U-M faculty and students with a move to UM’s North Campus Research Complex.
The Plymouth-based biopharmaceutical developer Lycera Corp. Thursday announced an exclusive research collaboration with pharma giant Merck to develop drug candidates that have the potential to treat major autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis
Scientists at the University of Michigan Heath System and their collaborators have found four new DNA “hotspots” that may one day help guide new treatments for psoriasis, one of the most common autoimmune diseases in […]
Millions of Americans struggling with psoriasis and psoriatic arthritis are one step closer to a cure with the release of the first National Psoriasis Victor Henschel BioBank DNA samples for use in research at the […]
Allegan-based Perrigo Co. (Nasdaq: PRGO) announced its filing with the United States Food and Drug Administration for its Abbreviated New Drug Application for clobetasol propionate shampoo, 0.05 percent, and notified Galderma, the listed patent owner.